Shah S A, Peppercorn M A
Department of Medicine, Beth Israel Hospital, Harvard Medical School, Boston, MA 02215, USA.
Compr Ther. 1995 Jun;21(6):296-302.
The armamentarium for the treatment of IBD has grown considerably within the last decade. Sulfasalazine and corticosteroids, the two cornerstones of past therapy, are now joined by the 5-ASA drugs, antibiotics, immunosuppressive agents, and newer corticosteroids. In addition, several novel therapies with promising initial results are being investigated. As the mechanisms by which these agents work are elucidated, further insight into the pathogenesis of IBD will be gained. Based on the nature and extent of disease, physicians and patients will be able to select the optimal agent or therapeutic combination for control of this enigmatic and morbid disease.
在过去十年中，治疗炎症性肠病（IBD）的手段有了显著增加。过去治疗的两大基石——柳氮磺胺吡啶和皮质类固醇，如今又有了5-氨基水杨酸（5-ASA）类药物、抗生素、免疫抑制剂以及新型皮质类固醇。此外，几种初步结果颇具前景的新型疗法也在研究之中。随着这些药物作用机制的阐明，对IBD发病机制将有更深入的了解。根据疾病的性质和程度，医生和患者将能够选择最佳药物或治疗组合来控制这种神秘且有害的疾病。
